Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.60 |
| ▸ | TNK2 | Q07912 | 13/20 | 0.50 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122300 | 0.96 | BTK (0.61) | BTKTNK2ACVRL1HTR1ASLC6A2 | |
| SCHEMBL167539 | 0.95 | BTK (0.61) | BTKTNK2ACVRL1HTR1ASLC6A2 | |
| SCHEMBL170027 | 0.88 | BTK (0.61) | BTKTNK2 | |
| SCHEMBL175374 | 0.88 | BTK (0.69) | BTKTNK2ACVRL1HTR2CHTR2B | |
| SCHEMBL175885 | 0.88 | BTK (0.47) | BTKTNK2HTR2CHTR2BHTR1A | |
| SCHEMBL123477 | 0.86 | BTK (0.56) | BTKTNK2ACVRL1HTR1ASLC6A2 | |
| SCHEMBL169823 | 0.86 | BTK (0.61) | BTKTNK2ACVRL1 | |
| SCHEMBL168773 | 0.85 | TNK2 (0.50) | BTKTNK2ACVRL1 | |
| SCHEMBL122913 | 0.85 | BTK (0.60) | BTKTNK2ACVRL1 | |
| SCHEMBL121733 | 0.84 | BTK (0.54) | BTKTNK2ACVRL1HTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | claimed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | claimed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | claimed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | claimed |
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | ROTHBAUM WAYNE (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140357636-A1 | Treatment of Skeletal-Related Disorders | ROTHBAUM WAYNE (US) | 2014-12-04 | — | — | US | disclosed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-2139483-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | Exelixis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | SOST, COL2A1, CYP27B1 | BTK 4374/4885TNK2 1030/4885ACVRL1 1899/4885 |
| US-20140357636-A1 | Treatment of Skeletal-Related Disorders | SOST, COL2A1, CYP27B1 | BTK 4374/4885TNK2 1030/4885ACVRL1 1899/4885 |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | BTK 1/4885TNK2 511/4885ACVRL1 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.